Chiasma, Inc. (CHMA) Misses Q4 EPS by 8c

Chiasma, Inc. (NASDAQ: CHMA) reported Q4 EPS of ($0.61), $0.08 worse than the analyst estimate of ($0.53).

Cash, cash equivalents and marketable securities as of December 31, 2015 were $148.8 million, compared to $162.8 million as of September 30, 2015, primarily reflecting the company’s fourth-quarter operating expenditures. The company continues to expect that its cash resources will be sufficient to operate its business as currently planned through at least mid-2017.

Financial Guidance

Assuming approval of Mycapssa in April 2016, Chiasma expects its total aggregate GAAP research and development and selling, general and administrative expenses for full year 2016 to be in a range of $80 million to $88 million, which includes expected stock-based compensation expense of $7 million to $8 million. These planned expenditures are expected to include investments in:

• Mycapssa’s initial commercial launch for adult patients with acromegaly,
• The company’s pivotal EU Phase 3 trial in acromegaly,
• The initiation of a clinical trial of octreotide capsules supporting the potential treatment of patients with neuroendocrine tumors (NET) in late 2016, and
• The advancement of preclinical work that would enable the company to announce its second product candidate by the end of 2016.

For earnings history and earnings-related data on Chiasma, Inc. (CHMA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery